Refractory Anemia With Excess Blasts in Transformation Recruiting Phase 2 Trials for Filgrastim (DB00099)

Also known as: Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / Refractory anaemia with excess blasts in transformation / Myelodysplastic syndrome transformation

IndicationStatusPhase
DBCOND0028567 (Refractory Anemia With Excess Blasts in Transformation)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00357565Hematopoietic Stem Cell Transplantation in the Treatment of Infant LeukemiaTreatment